These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322 [TBL] [Abstract][Full Text] [Related]
7. A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model. Kwilas AR; Ardiani A; Dirmeier U; Wottawah C; Schlom J; Hodge JW Oncotarget; 2015 Sep; 6(29):28194-210. PubMed ID: 26317648 [TBL] [Abstract][Full Text] [Related]
8. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway. Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728 [TBL] [Abstract][Full Text] [Related]
9. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622 [TBL] [Abstract][Full Text] [Related]
10. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Bennett LL; Ingason A Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946 [TBL] [Abstract][Full Text] [Related]
11. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH Molecules; 2020 May; 25(10):. PubMed ID: 32456317 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193 [TBL] [Abstract][Full Text] [Related]
15. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B; N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer. Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647 [TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
19. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990 [TBL] [Abstract][Full Text] [Related]
20. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]